Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.

Endo shareholders will get $80 million in cash and own 49.9% of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion, the companies said ...

While Mallinckrodt emerged from its second bankruptcy in November 2023, Endo returned last year. The drugmakers are discussing the terms of a transaction that would give each of them roughly 50% ...

Mallinckrodt and Endo (NDOI.PK), opens new tab, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced plans Thursday to join forces in a deal valued at ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people with knowledge of the matter said. The drugmakers, which both emerged ...